Related to India Orders First Compulsory License for Bayer's Nexavar Cancer Drug to Natco

• Pfizer Teams with SFJ on Phase III Study of Axitinib in Asia
  
• USPTO Balks at Grant/Loan Program to Help Startups Protect Patents
  
• Bayer Plans 2012 Filing for Regorafenib Following Positive Phase III mCRC Trial Results
  
• Pfizer’s Inlyta Approved in U.S. as Therapy for Advanced Renal Cell Carcinoma
  
• India's Top Court Set to Hear Novartis Challenge to Patent Law
  
• Epistem Signs Up Xcelris to Distribute POC Diagnostic for TB in India
  
• Regeneron, Bayer Confirm Australian Approval of Eylea for Wet AMD
  
• India’s Proposed Budget Offers Some More Incentives, Taxes for Biopharma
  
• Currency Exchange Rates Deflate Sales, Profits for 75 Publicly Traded Pharmas in India
  
• Big Pharma Saw an Almost One-Third Drop in Patent Filings Between 2007 and 2009
  
• Supreme Court Unanimously Overturns Prometheus Dosage Calibration Method Patent
  
• With Acquisition of Bayer Imaging R&D Portfolio, Piramal Continues Shift to Pharma IP
  
• Santen Nabs Japanese Co-Promotion Rights to Bayer and Regeneron’s Eylea
  
• Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting
  
• Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC
  
• Bayer’s Regorafenib Met Primary PFS Endpoint in Late-Stage GIST Trial
  
• Trovagene, Strand Ally to Bring Urine HPV Dx to India and South Asia
  
• FDA Fails to Back Janssen, Bayer’s Xarelto for Acute Coronary Syndrome
  
• Ascletis Nabs Chinese Rights to Alnylam’s Liver Cancer RNAi
  
• New Malaria Vaccine in the Works